{
    "nctId": "NCT00191815",
    "briefTitle": "Combination Chemotherapy for Metastatic Breast Cancer",
    "officialTitle": "Phase II Study of Gemcitabine Plus Cisplatin as First-line Treatment of Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Objective Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* You are female in the age of 18 to 75 years old.\n* You have been diagnosed with the metastatic breast cancer.\n* You have desire and an opportunity to visit your doctor in medical site, both during realization of the active treatment program, and within 24 months of medical follow up.\n* You must sign this informed consent form\n\nExclusion Criteria:\n\n* You are pregnant or breastfeeding.\n* Your laboratory parameters fall outside the limits, admitted by requirements of the present clinical study.\n* You have been diagnosed with serious concomitant or acute infectious disease.\n* You have used experimental medications within the last month.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}